Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02773030 · ClinicalTrials.gov registry record · Phase 1

A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple Myeloma

A Phase 1 study of Multiple Myeloma, sponsored by Celgene.

Active
Registry status
Phase 1
Development phase
466
Enrollment target
20
Study locations

NCT02773030 is a Phase 1 study of Multiple Myeloma that is active but no longer recruiting, run by Celgene. The registered enrollment target is 466 participants, below the 546-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (15% lower). The trial reports 20 study locations across 8 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02773030, a Phase 1 study of Multiple Myeloma, is active but no longer recruiting, sponsored by Celgene.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
466 participants
Enrollment target
20
Study locations

Study Summary

This is a multicenter, multi-country, open-label, Phase 1b/2a dose-escalation study consisting of two parts: dose escalation (Part 1) for CC-220 monotherapy, CC-220 in combination with DEX, CC-220 in combination with DEX and DARA, CC-220 in combination with DEX and BTZ and CC-220 in combination with DEX and CFZ; and the expansion of the RP2D (Part 2) for CC-220 in combination with DEX for Relapsed Refractory Multiple Myeloma and CC-220 in combination with DEX and BTZ for Newly Diagnosed Multiple Myeloma.

Conditions Studied

Multiple Myeloma

Interventions

  • DRUG Dexamethasone
  • DRUG Daratumumab
  • DRUG Carfilzomib
  • DRUG Bortezomib
  • DRUG CC-220

Study Locations (20)

Massachusetts

  • Beth Israel Deaconess Medical Center - Boston
  • Local Institution - 114 - Boston
  • Local Institution - 115 - Boston
  • Massachusetts General Hospital - Boston
  • Dana-Farber/Mass General Brigham Cancer Care, Inc - Boston
  • Local Institution - 110 - Boston

Arizona

  • Local Institution - 102 - Scottsdale
  • Mayo Clinic - Scottsdale

Arkansas

  • Local Institution - 107 - Little Rock
  • University of Arkansas for Medical Sciences - Little Rock

Georgia

  • Local Institution - 101 - Atlanta
  • Winship Cancer Institute of Emory University - Atlanta

Illinois

  • Local Institution - 120 - Chicago
  • Robert H Lurie Comprehensive Cancer Center NW Univ - Chicago

Kansas

  • Local Institution - 113 - Fairway
  • University of Kansas Cancer Center - Fairway

Maryland

  • Local Institution - 106 - Baltimore
  • University of Maryland School of Med - Baltimore

Michigan

  • Local Institution - 104 - Ann Arbor
  • University of Michigan Comprehensive Cancer Center - Ann Arbor

Trial Details

FieldValue
Enrollment Target 466 participants
Start Date 2016-10-14
Est. Completion 2028-07-28
Phase Phase 1

Sponsor

Celgene

308 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02773030

The ClinicalTrials.gov registry entry for NCT02773030 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 466 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 546-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (15% lower). The listed sponsor is Celgene, which has 308 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Multiple Myeloma appearing as the primary indexed condition, and to 5 interventions - of which Dexamethasone is the first listed.

NCT02773030 reports 20 study locations spanning 8 distinct geographic areas - top geographies include Massachusetts, Arizona, Arkansas.

Frequently Asked Questions

What is clinical trial NCT02773030 about?

NCT02773030 is a clinical study titled "A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple Myeloma". This is a multicenter, multi-country, open-label, Phase 1b/2a dose-escalation study consisting of two parts: dose escalation (Part 1) for CC-220 monotherapy, CC-220 in combination with DEX, CC-220 in combination with DEX and DARA, CC-220 in combination with DEX and BTZ and CC-220 in combination with...

What is the current status of trial NCT02773030?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 466 participants. The study started on 2016-10-14. Estimated completion is 2028-07-28.

What conditions does trial NCT02773030 study?

This clinical trial studies the following conditions: Multiple Myeloma.

What interventions are being tested in trial NCT02773030?

The interventions under investigation include: Dexamethasone (DRUG), Daratumumab (DRUG), Carfilzomib (DRUG), Bortezomib (DRUG), CC-220 (DRUG).

Who is sponsoring clinical trial NCT02773030?

This trial is sponsored by Celgene, which has 308 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02773030 being conducted?

This trial has 20 study locations across Arizona, Arkansas, Georgia, Illinois, Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Multiple Myeloma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Multiple Myeloma

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.